Actively Recruiting

Phase 4
Age: 18Years - 29Years
MALE
Healthy Volunteers
NCT06468462

Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM

Led by University of Washington · Updated on 2025-11-19

2900

Participants Needed

3

Research Sites

182 weeks

Total Duration

On this page

Sponsors

U

University of Washington

Lead Sponsor

A

Aurum Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-recommended periodic presumptive treatment (PPT) or doxycycline post-exposure prophylaxis (doxyPEP), compared to standard syndromic treatment, with 18 months of follow-up and rigorous culture-based and molecular analysis of antimicrobial resistance in Neisseria gonorrhoeae. This work will provide critical data needed to inform guidelines and improve STI control among MSM in sub-Saharan Africa and other resource-limited settings, including modelled estimates of the health and economic impact of scaling up these two interventions on STI control among MSM and their partners in Kenya.

CONDITIONS

Official Title

Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM

Who Can Participate

Age: 18Years - 29Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 to 29 years old
  • Assigned male sex at birth
  • Identifies as male (cisgender)
  • Reports condomless anal intercourse with a man in the past 6 months
  • Reports multiple male sex partners or a male partner with a syndromic or laboratory-diagnosed STI in the past 6 months
  • Willing and able to provide written informed consent and participate in all study procedures
  • Planning to remain in the study area for 18 months
Not Eligible

You will not qualify if you...

  • Unable to understand the study purpose and procedures
  • Allergy to cephalosporin, macrolide, or tetracycline class antibiotics
  • Recent use of a prolonged antibiotic course (14 days or more) in the month before enrollment
  • Use of medications that affect metabolism of cefixime, azithromycin, or doxycycline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Anza Mapema Clinic

Kisumu, Kenya

Actively Recruiting

2

University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa

Mombasa, Kenya

Actively Recruiting

3

TRANSFORM Clinic

Nairobi, Kenya

Actively Recruiting

Loading map...

Research Team

S

Susan M Graham, MD, PhD, MPH

CONTACT

E

Eduard J Sanders, MD, PhD, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here